Mohini Kamra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohini Kamra has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Sapun H. Parekh
Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA
4 shared publications - Elif Sarinay Cenik
Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA
2 shared publications - Jeongsoo Kim
Chandra Department of Electrical and Computer Engineering, University of Texas at Austin, Austin, TX, USA
2 shared publications - Johann K. Eberhart
University of Texas at Austin
2 shared publications - Karin Allenspach
College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
2 shared publications - Khashayar Moshksayan
Walker Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 43 (1) , 32
The status quo and evolution of glycoconjugates for cancer immunotherapy
Glycans and glycoconjugates play a significant role in nearly all aspects of living organisms from birth through development to demise. For more than half a century, the aberrant glycosylation profiles on tumor cells have been discussed. However, in the past few decades scientists have validated how these modified glycans influence cancer development, progression and metastasis through bypassing immune surveillance and creating an immunosuppressive milieu in the tumor microenvironment. Although advancements in cancer immunotherapy have shown promise, it has only been able to enhance the overall survival of a small group of patients. Certain types of cancer remain undiagnosed and untreated until very late stages, due to the limited understanding of complex tumor immune resistance. The understanding and use of glycans and glycoconjugates help researchers to work towards broadening the benefits of cancer immunotherapy to a larger population. Many glycans and glycoconjugates have made their way to clinical trials but still the full potential of glycan-based materials has not been entirely harnessed. This comprehensive review outlines major developments in the field of glycoconjugate mediated cancer immunotherapy, with special emphasis on the most recent developments. While covering a wide range of glycan categories, attempts have been made to draw correlations between glycoconjugate structure and the primary immune response elicited by each of those glycan categories.
- 28 October 2026
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 43 (1) , 32
Open AccessThe status quo and evolution of glycoconjugates for cancer immunotherapy
Glycans and glycoconjugates play a significant role in nearly all aspects of living organisms from birth through development to demise. For more than half a century, the aberrant glycosylation profiles on tumor cells have been discussed. However, in the past few decades scientists have validated how these modified glycans influence cancer development, progression and metastasis through bypassing immune surveillance and creating an immunosuppressive milieu in the tumor microenvironment. Although advancements in cancer immunotherapy have shown promise, it has only been able to enhance the overall survival of a small group of patients. Certain types of cancer remain undiagnosed and untreated until very late stages, due to the limited understanding of complex tumor immune resistance. The understanding and use of glycans and glycoconjugates help researchers to work towards broadening the benefits of cancer immunotherapy to a larger population. Many glycans and glycoconjugates have made their way to clinical trials but still the full potential of glycan-based materials has not been entirely harnessed. This comprehensive review outlines major developments in the field of glycoconjugate mediated cancer immunotherapy, with special emphasis on the most recent developments. While covering a wide range of glycan categories, attempts have been made to draw correlations between glycoconjugate structure and the primary immune response elicited by each of those glycan categories.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Inverse scattering in biological samples via beam propagation
Multiple scattering limits optical imaging in thick biological samples by scrambling sample-specific information. Physics-based inverse-scattering methods aim to computationally unscramble this information often by using nonconvex optimization solvers. However, their inherent nonconvexity often leads to highly sample-dependent performance and inaccurate reconstructions, particularly in strongly scattering specimens. Here, we introduce a novel inverse-scattering framework based on multislice beam propagation (MSBP) that robustly achieves high-quality scatter correction and label-free volumetric imaging across a diverse range of scattering biological samples. We rigorously benchmarked imaging performance across multiple MSBP solver implementations using both scattering calibration phantoms and biological specimens. We found that an amplitude-only cost function in the inverse solver, combined with angular and defocus diversity in the scattering measurements, enabled volumetric, label-free imaging with high-quality and subcellular-level scatter correction. Together, these results establish a foundation for the reliable application of inverse scattering to achieve biologically interpretable three-dimensional imaging in increasingly thick, multicellular samples, thus introducing a new paradigm for deep-tissue computational imaging.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Inverse scattering in biological samples via beam propagation
Multiple scattering limits optical imaging in thick biological samples by scrambling sample-specific information. Physics-based inverse-scattering methods aim to computationally unscramble this information often by using nonconvex optimization solvers. However, their inherent nonconvexity often leads to highly sample-dependent performance and inaccurate reconstructions, particularly in strongly scattering specimens. Here, we introduce a novel inverse-scattering framework based on multislice beam propagation (MSBP) that robustly achieves high-quality scatter correction and label-free volumetric imaging across a diverse range of scattering biological samples. We rigorously benchmarked imaging performance across multiple MSBP solver implementations using both scattering calibration phantoms and biological specimens. We found that an amplitude-only cost function in the inverse solver, combined with angular and defocus diversity in the scattering measurements, enabled volumetric, label-free imaging with high-quality and subcellular-level scatter correction. Together, these results establish a foundation for the reliable application of inverse scattering to achieve biologically interpretable three-dimensional imaging in increasingly thick, multicellular samples, thus introducing a new paradigm for deep-tissue computational imaging.
- 20 November 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 209, 183-193
Collagen nanofiber alignment attenuates leader-follower energetic and metabolic differences during collective migration in pancreatic cancer
- 20 November 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 209, 183-193
Collagen nanofiber alignment attenuates leader-follower energetic and metabolic differences during collective migration in pancreatic cancer
- Open Access
Inverse-scattering in biological samples via beam-propagation
Multiple scattering limits optical imaging in thick biological samples by scrambling sample-specific information. Physics-based inverse-scattering methods aim to computationally recover this information, often using non-convex optimization to reconstruct the scatter-corrected sample. However, this non-convexity can lead to inaccurate reconstructions, especially in highly scattering samples. Here, we show that various implementation strategies for even the same inverse-scattering method significantly affect reconstruction quality. We demonstrate this using multi-slice beam propagation (MSBP), a relatively simple nonconvex inverse-scattering method that reconstructs a scattering sample’s 3D refractive-index (RI). By systematically conducting MSBP-based inverse-scattering on both phantoms and biological samples, we showed that an amplitude-only cost function in the inverse-solver, combined with angular and defocus diversity in the scattering measurements, enabled high-quality, fully-volumetric RI imaging. This approach achieved subcellular resolution and label-free 3D contrast across diverse, multiple-scattering samples. These results lay the groundwork for robust use of inverse-scattering techniques to achieve biologically interpretable 3D imaging in increasingly thick, multicellular samples, introducing a new paradigm for deep-tissue computational imaging.
Open AccessInverse-scattering in biological samples via beam-propagation
Multiple scattering limits optical imaging in thick biological samples by scrambling sample-specific information. Physics-based inverse-scattering methods aim to computationally recover this information, often using non-convex optimization to reconstruct the scatter-corrected sample. However, this non-convexity can lead to inaccurate reconstructions, especially in highly scattering samples. Here, we show that various implementation strategies for even the same inverse-scattering method significantly affect reconstruction quality. We demonstrate this using multi-slice beam propagation (MSBP), a relatively simple nonconvex inverse-scattering method that reconstructs a scattering sample’s 3D refractive-index (RI). By systematically conducting MSBP-based inverse-scattering on both phantoms and biological samples, we showed that an amplitude-only cost function in the inverse-solver, combined with angular and defocus diversity in the scattering measurements, enabled high-quality, fully-volumetric RI imaging. This approach achieved subcellular resolution and label-free 3D contrast across diverse, multiple-scattering samples. These results lay the groundwork for robust use of inverse-scattering techniques to achieve biologically interpretable 3D imaging in increasingly thick, multicellular samples, introducing a new paradigm for deep-tissue computational imaging.
- Open Access
- 30 September 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (41)
Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections
Despite much research, considerable data suggest that influenza virus remains a serious health problem because i) the effectiveness of current vaccines ranges only from 19% to 60%, ii) available therapies remain ineffective in advanced stages of disease, iii) death rates vary between 25,000 and 72,000/year in the United States, and iv) avian influenza strains are now being transmitted to dairy cattle that in turn are infecting humans. To address these concerns, we have developed zanDR, a bispecific small molecule that binds and inhibits viral neuraminidase expressed on both free virus and virus-infected cells and recruits naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens. Because the neuraminidase inhibition replicates the chemotherapeutic mechanism of zanamivir and oseltamivir, while rhamnose and DNP recruit endogenous antibodies much like an anti-influenza vaccine, zanDR reproduces most of the functions of current methods of protection against influenza virus infections. Importantly, studies on cells in culture demonstrate that both of the above protective mechanisms remain highly functional in the zanDR conjugate, while studies in lethally infected mice with advanced-stage disease establish that a single intranasal dose of zanDR not only yields 100% protection but also reduces lung viral loads faster and ~1,000× more thoroughly than current antiviral therapies. Since zanDR also lowers secretion of proinflammatory cytokines and protects against virus-induced damage to the lungs better than current therapies, we suggest that combining an immunotherapy with a chemotherapy in single pharmacological agent constitutes a promising approach for treating the more challenging forms of influenza.
- 30 September 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (41)
Open AccessTargeted recruitment of immune effector cells for rapid eradication of influenza virus infections
Despite much research, considerable data suggest that influenza virus remains a serious health problem because i) the effectiveness of current vaccines ranges only from 19% to 60%, ii) available therapies remain ineffective in advanced stages of disease, iii) death rates vary between 25,000 and 72,000/year in the United States, and iv) avian influenza strains are now being transmitted to dairy cattle that in turn are infecting humans. To address these concerns, we have developed zanDR, a bispecific small molecule that binds and inhibits viral neuraminidase expressed on both free virus and virus-infected cells and recruits naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens. Because the neuraminidase inhibition replicates the chemotherapeutic mechanism of zanamivir and oseltamivir, while rhamnose and DNP recruit endogenous antibodies much like an anti-influenza vaccine, zanDR reproduces most of the functions of current methods of protection against influenza virus infections. Importantly, studies on cells in culture demonstrate that both of the above protective mechanisms remain highly functional in the zanDR conjugate, while studies in lethally infected mice with advanced-stage disease establish that a single intranasal dose of zanDR not only yields 100% protection but also reduces lung viral loads faster and ~1,000× more thoroughly than current antiviral therapies. Since zanDR also lowers secretion of proinflammatory cytokines and protects against virus-induced damage to the lungs better than current therapies, we suggest that combining an immunotherapy with a chemotherapy in single pharmacological agent constitutes a promising approach for treating the more challenging forms of influenza.
- Open Access
Ketomimetic Nutrients Trigger a Dual Metabolic Defense in Breast Cancer Cells
While the triggers for the metastatic transformation of breast cancer (BC) cells remain unknown, recent evidence suggests that intrinsic cellular metabolism could be a crucial driver of migratory disposition and chemoresistance. Aiming to decode the molecular mechanisms involved in BC cell metabolic maneuvering, we study how a ketomimetic (ketone body-rich, low glucose) medium affects Doxorubicin (DOX) susceptibility and invasive disposition of BC cells. We quantified glycocalyx sialylation and found an inverse correlation with DOX-induced cytotoxicity and DOX internalization. These measurements were coupled with single-cell metabolic imaging, bulk migration studies, along with transcriptomic and metabolomic analyses. Our findings revealed that a ketomimetic medium enhances chemoresistance and invasive disposition of BC cells via two main oncogenic pathways: hypersialylation and lipid synthesis. We propose that the crosstalk between these pathways, juxtaposed at the synthesis of the glycan precursor UDP-GlcNAc, furthers advancement of a metastatic phenotype in BC cells under ketomimetic conditions.
Open AccessKetomimetic Nutrients Trigger a Dual Metabolic Defense in Breast Cancer Cells
While the triggers for the metastatic transformation of breast cancer (BC) cells remain unknown, recent evidence suggests that intrinsic cellular metabolism could be a crucial driver of migratory disposition and chemoresistance. Aiming to decode the molecular mechanisms involved in BC cell metabolic maneuvering, we study how a ketomimetic (ketone body-rich, low glucose) medium affects Doxorubicin (DOX) susceptibility and invasive disposition of BC cells. We quantified glycocalyx sialylation and found an inverse correlation with DOX-induced cytotoxicity and DOX internalization. These measurements were coupled with single-cell metabolic imaging, bulk migration studies, along with transcriptomic and metabolomic analyses. Our findings revealed that a ketomimetic medium enhances chemoresistance and invasive disposition of BC cells via two main oncogenic pathways: hypersialylation and lipid synthesis. We propose that the crosstalk between these pathways, juxtaposed at the synthesis of the glycan precursor UDP-GlcNAc, furthers advancement of a metastatic phenotype in BC cells under ketomimetic conditions.